Platelet function and pharmacology of antiplatelet drugs

Cerebrovascular Diseases

Volumn 7, Issue , 1997, Pages 2-9

  Nurden, Alan T ^a   Guyonnet Duperat, Véronique ^a   Nurden, Paquita ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; COLLAGEN; DIPYRIDAMOLE; FIBRINOGEN; INTEGRIN; THROMBIN; THROMBOCYTE RECEPTOR; TICLOPIDINE; VITRONECTIN; VITRONECTIN RECEPTOR;

CEREBROVASCULAR DISEASE; CONFERENCE PAPER; HUMAN; PRIORITY JOURNAL; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOGENESIS;

EID: 9844246980     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000108274     Document Type: Article

References (46)

1. George JN, Nurden AT, Phillips DR: Molecular defects in interactions of platelets with the vessel wall. N Engl J Med 1984;311:1084-1098.
2. Roth GJ: Developing relationships: Arterial platelet adhesion, glycoprotein lb, and leucine-rich glycoproteins. Blood 1991;77:5-19.
3. Lopez JA: The platelet glycoprotein Ib-IX complex. Blood Coagul Fibrinolysis 1994;5:97-118.
4. Yao S-K, Ober JC, Garfinkel LI, Hagay Y, Ezov N, Ferguson JJ, Anderson V, Panet A, Górecki M, Buja M. Willerson JT: Blockade of platelet membrane glycoprotein lb receptors delays intracoronary thrombogenesis, enhances thrombolysis, and delays coronary artery reocclusion in dogs. Circulation 1994;89: 2822-2828.
5. Van Zanten GH, Connelly TM, Schiporst ME, de Graaf S. Slootweg PJ, Sixma JJ: Recombinant leech anti-platelet protein specifically blocks platelet deposition on collagen surfaces under flow conditions. Arterioscler Thromb Vase Biol 1995;15:1424-1431.
6. Morton LF. Hargreaves PG, Famdale RW, Young RD. Barnes MJ: Integrin cßrindepcn-dent activation of platelets by simple collagenlike peptides: Collagen tertiary (triple-helical) and quaternary (polymeric) structures are sufficient alone for a2pi-independent platelet reactivity. Biochem J 1995;306:337-344.
7. Fässler R, Georgcs-Labouessc E, Hirsch E: Genetic analyses of integrin function in mice. CurrOpin Dev Biol 1996;8:641-646.
8. vß3 for angiogenesis. Science 1994;264:569-571.
9. Topol EJ, Califf RM, Weismann HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT: Randomized trial of coronary interv ention with antibody against platelet GP Ilb/Illa integrin for reduction of clinical restenosis: Results at six months. Lancet 1994; 343:881-886.
10. Konkle BA, Shapiro SS, Asch AS, Nachman RL: Cytokine-enhanced expression of glycoprotein Iba in human endothelium. J Biol Chem 1990;265:19833-19838.
11. Schrör K: Antiplatelet drugs. A comparative review. Drugs 1995;50:7-28.
12. Turner M, Mee PJ, Costello PS, Williams O, Price AA, Duddy LP, Furlong MT, Geahlen RL, Tybulewicz VLJ: Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature 1995;378:298-302.
13. Mills DCB: ADP receptors on platelets. Thromb Haemost 1996;76:835-836.
14. Savi P, Heilmann E, Nurden P, Laplace MCL, Bihour C, Kieffer G, Nurden AT, Herbert JM: Clopidogrel: An antithrombotic drug acting on the ADP-dependcnt activation pathway of human platelets. Clin Appl Thromb Hemost 1996;2:35-42.
15. Léon C, Hechler B, Vial C, Leray C, Cazenave J-P, Gachet C: The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett 1997;403:26-30.
16. Humbert M, Nurden P, Bihour C, Coste P, Besse P, Nurden AT: Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vas Biol 1996;16:1532-1543.
17. Nurden P, Savi P, Heilmann E, Bihour C, Herbert J-M, Maffrand J-P, Nurden AT: An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. J Clin Invest 1995;95:1612-1622.
18. Gachet C, Hechler B, Léon C, Vial C, Ohlmann P, Cazenave J-P: Purinergic receptors on platelets. Platelets 1996;7:261-267.
19. Vu T-KH, Hung DT, Wheaton VI, Coughlin SR: Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991;64:1057-1068.
20. lshihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR: Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997; 386:502-506.
21. Herbert JM, Bemat A. Barthelemy G, Dol F, Rinaldi M: Antithrombotic activity of SR 46349, a novel, potent and selective 5-HTα1β1 receptor antagonist. Thromb Haemost 1993; 69:262-267.
22. Schomig A, Neumann F-J, Kastrati A, Schuh-len H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth E-M, Richardt G, Alt E, Schmitt C, Ulm K: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089.
23. KiefTer N, Phillips DR: Platelet membrane glycoproteins: Functions in cellular interactions. Annu Rev Cell Biol 1990;6:329-357.
24. Goto S, Salomon DR, Ikeda Y, Ruggeri ZM: Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets. J Biol Chem 1995;270:23352-23361.
25. George JN, Caen JP, Nurden AT: Glanz-mann’s thromboasthenia: The spectrum of clinical disease and molecular abnormalities in 64 patients. Blood 1990;75:1383-1395.
26. Coller BS: Blockade of platelet GPIIb/lIIa receptors as an antithrombotic strategy. Circulation 1995;92:2373-2380.
27. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, KJeiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ: Pharmacodynamics of chimeric glycoprotein Ilb/Illa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757-1764.
28. The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
29. Lefkovits J, Topol EJ: Platelet glycoprotein lib/ Ilia receptor agonists in coronary artery disease. Eur Heart J 1996;17:9-18.
30. Theroux P, Kouz S, Roy L, Knudtson ML, Dio-dati JG, Marquis J-F, Nasmith J, Fung AY, Boudrcaul JR, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ, on behalf of the investigators: Platelet membrane receptor glycoprotein Ilb/IIIa antagonism in unstable angina. The Canadian Lamiflban study. Circulation 1996:94:899-905.
31. Schulman SP, Goldschmidt-Clermont PJ. Topol EJ. Calilt RM. Navetta FI. Willcrson JT. Chandra NC. Guerci AD. Ferguson JJ. Harrington RA, Lincoln AM. Yakubov SJ. Bray PF. Bahr RD, Wolfe CL. Yock PG. Anderson HV, Nygaard TW, Mason SJ, Effron MB. Fat-terpackcr A. Raskin S. Smith J. Brashcars L. Gottdiener P. du Mce C. Kilt MM. Gcrstcn-blith G: Effects of integrilin, a platelet glycoprotein Ilb/IIIa receptor antagonist, in unstable angina. A randomized multicentcr trial. Circulation 1996:94:2053-2059.
32. Lefkovits J. Plow EF. Topol EJ: Platelet glycoprotein llb/llla receptors in cardiovascular medicine. N Engl J Med 1995:332:1553-1559.
33. Ecclcston D. Topol EJ: Inhibitors of platelet glycoprotein Ilb/IIIa as augmcnters of thrombolysis. Coronary Artery Dis 1995:6:947-955.
34. Ohmann EM, Klciman NS, Gacioch G, Worley SJ. Navetta FI. Talley D. Anderson V, Ellis SG. Cohen M. Sproggs D. Miller M. Kcraiakcs D. Yakubov S. Kilt MM. Sigmon K.N. Calilt RM. Krucofl MW, Topol EJ, for the IMPACT-AMI investigators: Combined accelerated tissuc-plasminogen activator and platelet glycoprotein Ilb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Results of a randomized, placebo-controllcd dose-ranging trial. Circulation 1997;95:846-854.
35. Shattil SJ. O'Toole T. Eigcnthalcr M. Thon V. Williams M. Babior BM. Ginsberg MIL α3β3-Endoncxin, a novel polypeptide that interacts specifically with the cytoplasmic tail of the integrin α3β3 subunit. J Cell Biol 1995:131: 807-816.
36. Hughes PE. Diaz-Gonzalcz F. Leong L. Wu C. McDonald JA. Shattil SJ. Ginsberg MH: Breaking the integrin hinge. A defined structural constraint regulates integrin signalling. J Biol Chcm 1996:271:6571-6574.
37. Van Willigen G. Hers I. Groter G. Akkcrman J-WN: Exposure of ligand-binding sites on platelet integrin α3β3, pi by phosphorylation of the pi subunit. Biochent J 1996:314:769-779.
38. Law DA. Nannizzi-Alaimo L. Phillips DR: Outside-in integrin signal transduction. um,ß.t-(GP llh-llla) tyrosine phosphorylation induced by platelet aggregation. J Biol Client 1996:271: 10811-10815.
39. Michelson AD: Flow cytometry: A clinical test of platelet function. Blood 1996:87:4925-4936.
40. Scharf RE. Tomer A. Marzcc UM. Teirstein PS. Ruggeri ZR. Marker LA: Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. Arteriosclerosis Tliromb 1992:12:1475-1487.
41. Bihour C, Durrieu-JaVs C, Macclii L, Coste P, Bcsse P, Nurden P, Nurden A: Expression of activation markers on platelets of patients receiving abciximab (c7E3 Fab: ReoPro) and undergoing percutaneous transluminal coronary angioplasty for refractory unstable angina. (Submitted.)
42. Reverter JC. Bcguin S. Kessels II. Kumar R. Hcmkcr HC. Coller BS: Inhibition of platelet-mediated. tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and ‘clinical restenosis'. J Clin Invest 1996:98:863-874.
43. Weiss ET. Bray PF. Payback M. Schulman SP. Kickler TS. Becker IC. Weiss JL. Gersicnblith G. Goldschmidt-Clermont PJ: A polymorphism of a platelet gylcoprolein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996:334:1090-1094.
44. u polymorphism of platelet glycoprotein Ilia and risks of myocardial infarction, stroke, and venous thrombosis. Lancet1997:349:385-388.
45. Nurden AT: Polymorphisms of human platelet membrane glycoproteins: Structure and clinical significance. Tliromb Haemost 1995:4: 345-351.
46. Kunicki TJ. Krilzik M. Annis DS. Nugent DJ: Hereditary variation in platelet integrin roß density is associated with two silent polymorphisms in the u; gene coding sequence. Blood 1997;89:1939-1943.